Companies in #Vascular Malformations

Palvella Therapeutics is a Wayne, Pennsylvania-based clinical-stage biopharmaceutical company developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations, anchored by its QTORIN proprietary topical delivery platform. The lead asset QTORIN 3.9% rapamycin anhydrous gel is being evaluated in the Phase 3 SELVA trial for microcystic lymphatic malformations (51 patients enrolled against a 40-patient target, with topline results expected in March 2026 and a rolling NDA submission planned for H2 2026 if endpoints are met). On June 29, 2026 Palvella submitted the first module of a rolling NDA to the FDA for QTORIN rapamycin in microcystic lymphatic malformations, and on July 14, 2026 the company filed a new corporate presentation on the SEC platform outlining QTORIN platform progress and growth plans. The QTORIN pitavastatin program is protected by a Yale-licensed U.S. patent providing protection into 2043. Palvella reported cash of $262M and a $1.96B market capitalization as of mid-July 2026.

Tectonic Therapeutic is a clinical-stage biotechnology company developing a pipeline of conformationally-stabilized G-protein-coupled receptor (GPCR) antibodies and other biologics, with an initial focus on cardiovascular disease. Its lead program, TX000045, is being developed for Hereditary Hemorrhagic Telangiectasia (HHT) and other vascular malformations driven by abnormal TGF-beta signaling. The company's platform is designed to enable antibody-based targeting of GPCRs and other traditionally difficult targets.